The Asia Pacific Allergy Immunotherapy Market should witness market growth of 9.4% CAGR during the forecast period (2023-2030).
Recent years have seen a substantial increase in interest in the immunotherapy treatment industry because of its novel approach to cancer treatment. It's crucial to remember that an expanding sector for allergy immunotherapy uses comparable immunotherapy techniques to treat allergies. Immunotherapy for allergies differs from immunotherapy for cancer, although there are some parallels between the two. Both utilize biologics to activate an immunological response while depending on the immune system to combat disease. The success of cancer immunotherapies has also generated interest in using comparable strategies for treating other disease states, including allergies.
This market is one of the fastest-growing segments in the healthcare sector, with various variables influencing the current environment. The expanding incidence of allergies, developments in biotechnology and immunology, and the demand for individualized medication are all significant incentives. Among other things, allergy immunotherapy is a medication that stops allergic reactions from food, grass pollen, dust, and bee venom. Allergy immunotherapy aids in the reduction of allergy symptoms, particularly those that frequently lead to rhinitis, asthma, and conjunctivitis.
The National Library of Medicine reports that in China, 10.54% and 9.99% of patients, respectively, self-reported having food and medication allergies. Additionally, 20.48% of patients overreacted to insect bites. India is experiencing a fast health transition, with the rising burden of non-communicable disease (NCD) surpassing the burden of communicable disease. For the prevention and control of NCDs, many programs by the government were launched with a focus on strengthening infrastructure, human resources, early diagnosis, referral, and management. The rising cases of non-communicable diseases with the increasing government programs for their treatment will further surge the market’s growth.
The China market dominated the Asia Pacific Allergy Immunotherapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $208.9 million by 2030. The Japan market is poised to grow at a CAGR of 8.7% during (2023-2030). Additionally, The India market would register a CAGR of 10.1% during (2023-2030).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Treatment Type, the market is segmented into Subcutaneous Immunotherapy (SCIT), and Sublingual Immunotherapy (SLIT) (Tablets, and Drops). Based on Allergy Type, the market is segmented into Allergic Rhinitis, Allergic Asthma, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc. (Mylan N.V.), Merck KGaA , NIOX Group plc , DMS Imaging SA, Adamis Pharmaceuticals Corporation, Stallergenes Greer International AG (B-Flexion), Allergy Therapeutics plc , DBV Technologies S.A., HAL Allergy B.V. (Droege International Group AG.), LETI Pharma, S.L.U.
Recent years have seen a substantial increase in interest in the immunotherapy treatment industry because of its novel approach to cancer treatment. It's crucial to remember that an expanding sector for allergy immunotherapy uses comparable immunotherapy techniques to treat allergies. Immunotherapy for allergies differs from immunotherapy for cancer, although there are some parallels between the two. Both utilize biologics to activate an immunological response while depending on the immune system to combat disease. The success of cancer immunotherapies has also generated interest in using comparable strategies for treating other disease states, including allergies.
This market is one of the fastest-growing segments in the healthcare sector, with various variables influencing the current environment. The expanding incidence of allergies, developments in biotechnology and immunology, and the demand for individualized medication are all significant incentives. Among other things, allergy immunotherapy is a medication that stops allergic reactions from food, grass pollen, dust, and bee venom. Allergy immunotherapy aids in the reduction of allergy symptoms, particularly those that frequently lead to rhinitis, asthma, and conjunctivitis.
The National Library of Medicine reports that in China, 10.54% and 9.99% of patients, respectively, self-reported having food and medication allergies. Additionally, 20.48% of patients overreacted to insect bites. India is experiencing a fast health transition, with the rising burden of non-communicable disease (NCD) surpassing the burden of communicable disease. For the prevention and control of NCDs, many programs by the government were launched with a focus on strengthening infrastructure, human resources, early diagnosis, referral, and management. The rising cases of non-communicable diseases with the increasing government programs for their treatment will further surge the market’s growth.
The China market dominated the Asia Pacific Allergy Immunotherapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $208.9 million by 2030. The Japan market is poised to grow at a CAGR of 8.7% during (2023-2030). Additionally, The India market would register a CAGR of 10.1% during (2023-2030).
Based on Distribution Channel, the market is segmented into Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy. Based on Treatment Type, the market is segmented into Subcutaneous Immunotherapy (SCIT), and Sublingual Immunotherapy (SLIT) (Tablets, and Drops). Based on Allergy Type, the market is segmented into Allergic Rhinitis, Allergic Asthma, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc. (Mylan N.V.), Merck KGaA , NIOX Group plc , DMS Imaging SA, Adamis Pharmaceuticals Corporation, Stallergenes Greer International AG (B-Flexion), Allergy Therapeutics plc , DBV Technologies S.A., HAL Allergy B.V. (Droege International Group AG.), LETI Pharma, S.L.U.
Scope of the Study
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Online Pharmacy
By Treatment Type
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
- Tablets
- Drops
By Allergy Type
- Allergic Rhinitis
- Allergic Asthma
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Viatris, Inc. (Mylan N.V.)
- Merck KGaA
- NIOX Group plc
- DMS Imaging SA
- Adamis Pharmaceuticals Corporation
- Stallergenes Greer International AG (B-Flexion)
- Allergy Therapeutics plc
- DBV Technologies S.A.
- HAL Allergy B.V. (Droege International Group AG.)
- LETI Pharma, S.L.U.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market At a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific Allergy Immunotherapy Market by Distribution Channel
Chapter 5. Asia Pacific Allergy Immunotherapy Market by Treatment Type
Chapter 6. Asia Pacific Allergy Immunotherapy Market by Allergy Type
Chapter 7. Asia Pacific Allergy Immunotherapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Viatris, Inc. (Mylan N.V.)
- Merck KGaA
- NIOX Group plc
- DMS Imaging SA
- Adamis Pharmaceuticals Corporation
- Stallergenes Greer International AG (B-Flexion)
- Allergy Therapeutics plc
- DBV Technologies S.A.
- HAL Allergy B.V. (Droege International Group AG.)
- LETI Pharma, S.L.U.
Methodology
LOADING...
